Dean Y Li
Director; Executive VP & President, MRL · 7 filings · Latest: Jun 17, 2026
Merck & Co., Inc.
RECURSION PHARMACEUTICALS, INC.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
MRK | Dean Y Li | Executive VP & President, MRL | Apr 29, 2026 | Option Exercise | $110.03 | 4,722 | $519.6K | 96,757.05 | |
MRK | DEAN LI | — | Feb 10, 2026 | Proposed Sale | $117.52 | 10,235 | $1.2M | — | |
MRK | Dean Y Li | Executive VP & President, MRL | Feb 10, 2026 | Sale | $117.52 | 10,235 | $1.2M | 92,035.05 | |
MRK | Dean Y Li | Executive VP & President, MRL | Feb 4, 2026 | Sale | $118.77 | 15,087 | $1.8M | 102,270.05 | |
MRK | Dean Y Li | Executive VP & President, MRL | Feb 4, 2026 | Option Exercise | $56.04 | 15,087 | $845.5K | 117,357.05 | |
MRK | DEAN LI | — | Feb 4, 2026 | Proposed Sale | $118.77 | 15,087 | $1.8M | — |